TABLE 1.
Characteristics of the 44 Patients
| Characteristic | Data* | % |
|---|---|---|
| Demographics | ||
|
| ||
| Median age at surgery (y) | 62 (range, 38–75) | |
| Median body weight (kg) | 70 (range, 43–123) | |
| Median18F-FDG dose (MBq) | 352 (range, 274–430) | |
| Sex (male/female) | 25/19 | 56.8/43.2 |
|
| ||
| Histology | ||
|
| ||
| Squamous cell carcinoma | 23 | 52.3 |
| Adenocarcinoma | 21 | 47.7 |
|
| ||
| Clinical stage at diagnosis | ||
|
| ||
| II | 6 | 13.6 |
| III | 35 | 79.5 |
| IV | 3 | 6.8 |
|
| ||
| Tumor location | ||
|
| ||
| Left lower lobe | 6 | 13.6 |
| Left upper lobe | 15 | 34.1 |
| Right lower lobe | 6 | 13.6 |
| Right middle lobe | 3 | 6.8 |
| Right upper lobe | 14 | 31.8 |
|
| ||
| Pathologic stage after chemotherapy | ||
|
| ||
| 0 | 3 | 6.8 |
| I | 5 | 11.4 |
| II | 10 | 22.7 |
| III | 25 | 56.8 |
| IV | 1 | 2.3 |
|
| ||
| CT-based clinical T-stage at diagnosis | ||
|
| ||
| cT1 | 3 | 6.8 |
| cT2 | 25 | 56.8 |
| cT3 | 9 | 20.5 |
| cT4 | 7 | 15.9 |
|
| ||
| Pathologic T-stage after chemotherapy | ||
|
| ||
| ypT0 | 3 | 6.8 |
| ypT1 | 5 | 11.4 |
| ypT2 | 10 | 22.7 |
| ypT3 | 25 | 56.8 |
| ypT4 | 1 | 2.3 |
|
| ||
| Chemotherapy | ||
|
| ||
| Median cycles | 3 (range, 2–6) | |
| Platinum/gemcitabine | 17 | 51.6 |
| Platinum/taxane | 25 | 56.8 |
| Other | 3 | 6.8 |
*
Data are n, except where otherwise indicated.